Julie Schiffman

Vice President, Business Analytics, Pfizer Inc.

Julie Schiffman is Vice President of the Business Analytics (BA) organization at Pfizer. BA delivers business development, pipeline and commercial analytics as well as competitive intelligence to the enterprise.  BA provides a coordinated and synergistic view of competitive and business issues across our portfolio of investigational medicines, in-line medicines, and potential new business development opportunities.

Prior to her BA role, Julie led the Portfolio and Decision Analysis (PDA) group. PDA plays a critical role in identifying and advising senior leadership on the key value drivers affecting Pfizer’s R&D productivity, as well as driving portfolio strategy, insights and decision making. In that role, Julie oversaw the economic valuation of more than 100 R&D projects within Pfizer’s development portfolio and was responsible for leading and facilitating the annual portfolio prioritization process. She also was responsible for monitoring overall portfolio health and sustainability as well as the long-term strategic implications of therapeutic area, stage gate, partnering and resource decisions.

With more than 15 years of experience in the pharmaceutical industry and 15 years at Pfizer, Julie has held a variety of leadership positions including Director, Team Leader in PDA supporting the Specialty Care, Emerging Markets and Established Products business units, and Director of Early Commercial Development where she led early development, strategy and licensing projects for candidates in the atherosclerosis and diabetes therapeutic areas.

Prior to joining Pfizer, Julie was a Senior Manager in the Life Sciences practice at Deloitte Consulting leading projects involving portfolio strategy, customer segmentation, scenario planning and post-merger integration. Julie received a bachelor’s degree in Organizational Behavior and Management and Political Science from Brown University, and a master’s degree in business from The Wharton School of the University of Pennsylvania.


My Sessions

Life Sciences Panel: Why do we need DA when we have AI?

Grays Peak

Pharmaceutical drug investment decisions rely heavily on data and data analytics to inform executive-level decision-making.  Recently, there is a focus on exploring new products and services in the digital arena in the hopes of unlocking value and improving decision quality.  The intent of machine learning and artificial intelligence is to translate relevant data and information […]

Life Sciences